SCHEMBL3355849

SCHEMBL3355849

COc1ccc(CC2COc3cc(O)c(OC)c(O)c3C2=O)cc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.66
MAPT P10636 3/20 0.66
HPGD P15428 2/20 0.66
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
ALOX12 P18054 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
MAOB P27338 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAP2K1 Q02750 1/20 0.43
SHBG P04278 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17547639 0.94 CYP3A4 (0.66) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL16246508 0.92 CYP3A4 (0.67) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL16246493 0.92 CYP3A4 (0.67) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL17547635 0.90 CYP3A4 (0.64) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL16264011 0.90 CYP3A4 (0.67) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL17547634 0.88 CYP3A4 (0.64) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL30368835 0.88 CYP3A4 (0.67) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL17536649 0.88 CYP3A4 (0.67) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL29906184 0.87 CYP3A4 (0.57) CYP3A4MAPTHPGDMEN1KMT2A
SCHEMBL29929340 0.87 CYP3A4 (0.57) CYP3A4MAPTHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2994460-B1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES UNIV INDIANA RES & TECH CORP (US) 2024-12-04 EP disclosed
CN-114469826-B Gel type radix ophiopogonis whitening mask and preparation method thereof 浙江省林业科学研究院 2023-11-14 CN disclosed
EP-3380194-B1 COMPOSITION FOR BLOCKING ANGIOGENESIS UNIV INDIANA RES & TECH CORP (US) 2023-11-01 EP disclosed
US-11707445-B2 Composition for blocking angiogenesis INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-07-25 US disclosed
US-11707445-B2 Composition for blocking angiogenesis INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-07-25 US disclosed
US-20220331258-A1 Poly-Dioxanone Multi-Block Copolymer for Ocular Protein Delivery ALLERGAN SALES, LLC (US) 2022-10-20 US disclosed
US-20210228538-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2021-07-29 US disclosed
US-10738024-B2 Compounds for treatment of angiogenesis-mediated diseases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2020-08-11 US disclosed
US-10238627-B2 Compounds for treatment of angiogenesis-mediated diseases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-03-26 US disclosed
US-20180353464-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-12-13 US disclosed
EP-3380194-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS Indiana University Research & Technology Corporation (US) 2018-10-03 EP disclosed
US-20180177758-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-06-28 US disclosed
WO-2017091473-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2017-06-01 WO disclosed
US-20160060241-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2016-03-03 US disclosed
US-20160060241-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2016-03-03 US disclosed
WO-2014182695-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2014-11-13 WO disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 US disclosed
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2011-12-08 US disclosed
WO-2010039679-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331258-A1 Poly-Dioxanone Multi-Block Copolymer for Ocular Protein Delivery UACA, DBI, PEBP1 CYP3A4 3912/4885MAPT 3969/4885HPGD 3954/4885
US-11707445-B2 Composition for blocking angiogenesis FLT4, KDR, VEGFA CYP3A4 4634/4885MAPT 2741/4885HPGD 573/4885
US-10738024-B2 Compounds for treatment of angiogenesis-mediated diseases KDR, TEK, VEGFA CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885
US-20180353464-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS FLT4, KDR, VEGFA CYP3A4 4634/4885MAPT 2741/4885HPGD 573/4885
US-20210228538-A1 COMPOSITION FOR BLOCKING ANGIOGENESIS FLT4, KDR, VEGFA CYP3A4 4634/4885MAPT 2741/4885HPGD 573/4885
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 CYP3A4 4005/4885MAPT 2714/4885HPGD 1712/4885
US-20180177758-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES KDR, TEK, VEGFA CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885
US-20160060241-A1 COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES KDR, TEK, VEGFA CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885
US-10238627-B2 Compounds for treatment of angiogenesis-mediated diseases KDR, TEK, VEGFA CYP3A4 3509/4885MAPT 3088/4885HPGD 32/4885
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 CYP3A4 4005/4885MAPT 2714/4885HPGD 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.